<DOC>
	<DOCNO>NCT01210001</DOCNO>
	<brief_summary>This study investigate efficacy safety BI 10773 type 2 diabetic patient order provide data approval BI 10773 regulatory authority antidiabetic agent add-on therapy pioglitazone alone combination metformin .</brief_summary>
	<brief_title>Efficacy Safety Empagliflozin ( BI 10773 ) Type 2 Diabetes Patients Background Pioglitazone Alone With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis type 2 diabetes mellitus prior inform consent . 2 . Male female patient diet exercise regimen pretreated pioglitazone alone combination metformin . The treatment regimen unchanged 12 week prior randomisation . 3 . HbA1c &gt; /= 7.0 % &lt; /= 10.0 % Visit 1 ( screen ) . 4 . Age &gt; /= 18 . 5 . BMI &lt; /= 45 kg/m2 ( Body Mass Index ) Visit 1 ( screen ) . 6 . Signed date write informed consent date Visit 1 accordance Good Clinical Practice ( GCP ) local legislation . Exclusion criterion : 1 . Uncontrolled hyperglycaemia glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/l ) overnight fast placebo runin confirm second measurement ( day ) . 2 . Any antidiabetic medication within 12 week prior randomisation , except define permitted background therapy via inclusion criterion . 2 . 3 . Myocardial infarction , stroke transient ischaemic attack ( TIA ) within 3 month prior inform consent . 4 . Indication liver disease , define serum level either alanine transaminase ( ALT/SGPT ) , aspartate transaminase ( AST/SGOT ) , alkaline phosphatase 3 x upper limit normal ( ULN ) determine screen placebo runin period ( i.e . visit prior randomisation visit , Visit 3 ) . 5 . Impaired renal function , define eGFR ( estimate Glomerular Filtration Rate ) &lt; 30 ml/min ( severe renal impairment , MDRD [ Modification Diet Renal Disease ] formula ) determine screen placebo runin period ( i.e . visit prior randomisation visit , Visit 3 ) . 6 . Bariatric surgery within past two year gastrointestinal surgery induce chronic malabsorption . 7 . Medical history cancer ( except basal cell carcinoma ) and/or treatment cancer within last 5 year . 8 . Blood dyscrasia disorder cause haemolysis unstable red blood cell ( e.g . malaria , babesiosis , haemolytic anaemia ) . 9 . Contraindications pioglitazone accord local label . 10 . Contraindication pioglitazone and/or metformin ( relevant patient enter study background therapy ) accord local label . 11 . Treatment antiobesity drug ( e.g . sibutramine , orlistat ) 3 month prior inform consent treatment time screen ( i.e . surgery , aggressive diet regimen etc . ) lead unstable body weight . 12 . Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent uncontrolled endocrine disorder except T2D . 13 . Premenopausal woman ( last menstruation &lt; /= 1 year prior informed consent ) : nursing pregnant child bear potential practicing acceptable method birth control , plan continue use method throughout trial agree submit periodic pregnancy test participation trial . Acceptable method birth control include tubal ligation , transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , sexual abstinence ( acceptable local authority ) , double barrier method vasectomise partner . 14 . Alcohol drug abuse within 3 month prior inform consent would interfere trial participation ongoing condition lead decrease compliance study procedure study drug intake . 15 . Participation another trial investigational drug within 30 day prior informed consent . 16 . Any clinical condition would jeopardise patient safety participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>